OBJECT: Deep brain stimulation (DBS) has been recently investigated as a treatment for major depression. One of the proposed targets for this application is the subcallosal cingulate gyrus (SCG). To date, promising results after SCG DBS have been reported by a single center. In the present study the authors investigated whether these findings may be replicated at different institutions. They conducted a 3-center prospective open-label trial of SCG DBS for 12 months in patients with treatment-resistant depression. METHODS: Twenty-one patients underwent implantation of bilateral SCG electrodes. The authors examined the reduction in Hamilton Rating Scale for Depression (HRSD-17) score from baseline (RESP50). RESULTS: Patients treated with SCG DBS had an RESP50 of 57% at 1 month, 48% at 6 months, and 29% at 12 months. The response rate after 12 months of DBS, however, increased to 62% when defined as a reduction in the baseline HRSD-17 of 40% or more. Reductions in depressive symptomatology were associated with amelioration in disease severity in patients who responded to surgery. CONCLUSIONS: Overall, findings from this study corroborate the results of previous reports showing that outcome of SCG DBS may be replicated across centers.
OBJECT: Deep brain stimulation (DBS) has been recently investigated as a treatment for major depression. One of the proposed targets for this application is the subcallosal cingulate gyrus (SCG). To date, promising results after SCG DBS have been reported by a single center. In the present study the authors investigated whether these findings may be replicated at different institutions. They conducted a 3-center prospective open-label trial of SCG DBS for 12 months in patients with treatment-resistant depression. METHODS: Twenty-one patients underwent implantation of bilateral SCG electrodes. The authors examined the reduction in Hamilton Rating Scale for Depression (HRSD-17) score from baseline (RESP50). RESULTS:Patients treated with SCG DBS had an RESP50 of 57% at 1 month, 48% at 6 months, and 29% at 12 months. The response rate after 12 months of DBS, however, increased to 62% when defined as a reduction in the baseline HRSD-17 of 40% or more. Reductions in depressive symptomatology were associated with amelioration in disease severity in patients who responded to surgery. CONCLUSIONS: Overall, findings from this study corroborate the results of previous reports showing that outcome of SCG DBS may be replicated across centers.
Authors: Erika K Ross; Joo Pyung Kim; Megan L Settell; Seong Rok Han; Charles D Blaha; Hoon-Ki Min; Kendall H Lee Journal: Neuroimage Date: 2016-01-11 Impact factor: 6.556
Authors: Nir Lipsman; Tejas Sankar; Jonathan Downar; Sidney H Kennedy; Andres M Lozano; Peter Giacobbe Journal: CMAJ Date: 2013-07-29 Impact factor: 8.262
Authors: Hideo Suzuki; Joan L Luby; Kelly N Botteron; Rachel Dietrich; Mark P McAvoy; Deanna M Barch Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-05-10 Impact factor: 8.829
Authors: Maher A Quraan; Andrea B Protzner; Zafiris J Daskalakis; Peter Giacobbe; Chris W Tang; Sidney H Kennedy; Andres M Lozano; Mary P McAndrews Journal: Neuropsychopharmacology Date: 2013-11-28 Impact factor: 7.853